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Abstract 
Background: Previous studies of our group among bipolar offspring and bipolar twins showed significant higher 
prevalence’s and levels of antithyroid peroxidase antibodies (TPO-Abs) in offspring and co-twins (without a mood 
disorder) compared to controls, suggesting that TPO-Abs might be considered as vulnerability factor (trait marker) for 
BD development.
Objectives: Here we elucidate, in the same cohorts, but now after 12- and 6-year follow-up, whether TPO-abs should 
be considered as a ‘trait’ marker for BD. The present study aims to investigate whether TPO-Abs (1) are stable over 
time, (2) are associated with lithium-exposure, (3) share a common genetic background with BD and are related to 
psychopathology.
Results: In bipolar offspring and twins, the prevalence of TPO-Abs is stable over time (rs = .72 p < .001 resp. rs = .82, 
p < .001) and not associated with lithium use. At follow-up, an increased prevalence of TPO-abs was again observed in 
bipolar offspring (10,4% versus 4%) and higher TPO-abs titers were still present in co-twins of bipolar cases compared 
to control twins [mean 1.06 IU/ml (SD .82) versus mean .82 IU/ml (SD .67)], although statistical significance was lost.
Conclusions: Although our results show a trend toward an increased inherited risk of the co-occurrence of BD and 
thyroid autoimmunity, large-scale studies can only draw final conclusions. Nationwide epidemiological and GWAS 
studies reach such numbers and support the view of a possible common (autoimmune) etiology of severe mood 
disorders and chronic recurrent infections and autoimmunity, including thyroid autoimmunity.
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Background
Several cross-sectional studies demonstrated that 
autoantibodies to thyroid peroxidase (TPO-Abs) are 
about 1–2 times more prevalent in patients with bipolar 
disorder (BD) than in the general population (Kupka et al. 
2002; Chakrabarti 2011; Bergink et al. 2013). A causative 
role of TPO-Abs in the pathogenesis of BD is uncertain 
(Bochetta et al. 2016).
TPO-Abs only play a limited causative role in the 
pathogenesis of autoimmune thyroid failure by aiding 
in the destruction of thyroid cells (Groot de et al. 2000). 
Autoreactive T cells specific for thyroid antigens (also 
part of the thyroid autoimmune response) play a more 
prominent role in such destruction during the inflamma-
tory reaction in the thyroid induced by the T cell-medi-
ated autoimmune reaction (the so-called autoimmune 
thyroiditis of Hashimoto) (Rosmalen et  al. 2001). Nev-
ertheless, TPO-Abs are considered clinically useful 
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serum markers of a developing or ongoing autoimmune 
thyroiditis (AITD) and they often precede the clinical 
thyroid failure phase (i.e., raised TSH, reduced fT4) of 
autoimmune thyroiditis for many years. In the general 
population, the prevalence rate of TPO-Abs ranges from 
about 2–30% (Kabelitz et  al. 2003), depending on age 
(female > men) and gender (old > young).
The thyroid autoimmune response is an aberrant 
response to self-antigens. Genes such as MHC-related 
genes, genes involved in T cell regulation (CTLA-4, 
PTPN22) (Tomer and Huber 2009), and environmental fac-
tors as iodine (lithium in mood disorders) play prominent 
roles in the pathogenesis. Lithium has a destructive capac-
ity for thyroid cells and might play a role in modulating the 
thyroid autoimmune response (Wilson et al. 1991).
In two previous studies, we searched for indications 
of a genetic background for the relationship BD-thyroid 
autoimmunity. In a first study, among bipolar offspring 
(Dutch bipolar offspring: DBO) with a mean age of 
21 years, a borderline significant (p =  .05) higher preva-
lence (9%) of TPO-Abs in the DBO cohort as compared 
to healthy population controls of the same age (3%) was 
observed, the prevalence being the highest especially in 
the daughters, who showed a prevalence of 11% in DBO 
compared to 4% in healthy controls (p  =  .008). Since 
TPO-Ab positivity was not associated with the presence 
of a mood disorder, we interpreted the finding that BD 
and thyroid autoimmunity shared (an) inherited vulner-
ability factor(s) (Hillegers et al. 2007). In a second study 
among bipolar twins, our main finding was that co-twins 
of a bipolar index twin (without a mood disorder) had a 
higher prevalence and titer of TPO-Abs as compared to 
healthy control twins. In particular, monozygotic dis-
cordant twin pairs had significant higher TPO-Abs titers 
than dizygotic discordant twin pairs (Vonk et  al. 2007). 
These findings of both studies strengthened us in the 
view that BD and thyroid autoimmunity are rooted in 
the same underlying genetically determined disturbance, 
most likely an immune disturbance, responsible for both 
thyroid autoimmunity and BD development. For this 
reason, we considered TPO-abs as a potential vulner-
ability factor (‘trait’ marker) for the development of BD. 
However, a recently published study contrasted with 
above-described findings of our group. Cobo and col-
leagues were unable to find a familial association of BD 
and thyroid autoimmunity and concluded that only BD-I 
patients showed functional thyroid abnormalities, related 
to lithium treatment (Cobo et al. 2015). This study deter-
mined the presence of thyroid alterations (thyroglobulin, 
thyroperoxidase antibodies, TSH, and free T4 levels) in 
239 individuals affected with BD, 131 first-degree rela-
tives and 108 healthy controls, and did not find signifi-
cant functional thyroid abnormalities in the group of 
first-degree relatives. In addition, this study did not sup-
port a familial aggregation of thyroid autoantibodies pos-
itivity in pedigrees of BD-I.
We recently were able to re-investigate the DBO chil-
dren and many of the bipolar twins after 6 and 12 years, 
respectively (resp.), to re-evaluate the prevalence of TPO-
Abs (using the same techniques) in the two high-risk 
populations for BD. In the DBO cohort, we also assessed 
TPO-Abs titers in both biological parents, i.e., the bipolar 
index parent and the co-parent. The present study aims 
to elucidate whether TPO-abs is a ‘trait’ marker for BD. 
Therefore, we evaluated whether TPO-Abs (1) are stable 
over time, (2) are associated with lithium-exposure, (3) 
share a common genetic background (familial and twin 
associations) with BD and are related to the presence or 
development of psychopathology over time.
Experimental procedures
Population and procedure
The study population comprised bipolar family trios, 
bipolar twins, and controls from “The Dutch bipolar off-
spring study” and “The Dutch bipolar twin study.” Both 
studies received approval by the Medical Ethics Commit-
tee of UMCU. A written informed consent was obtained 
from all the participants. A detailed description of study 
design, recruitment procedure, exclusion criteria of both 
studies can be found in Hillegers et al. (2007), (DBO) and 
Vonk et al. (2007) (twins). Table 1 shows an overview of 
the demographic characteristics. 
Bipolar family trios
The bipolar family trios described herein belong to the 
Dutch bipolar offspring study in short, 140 offspring 
(mean age 16 years, range 12–21) from 86 families with 
one parent diagnosed with BD (74% BD type I and 26% 
BD type II) were recruited in the years 1997–1999 and 
followed for 12  years. Subjects were assessed at four 
time-points: baseline and 1-, 5-, and 12-year follow-up 
with a retention rate of 77% (n  =  108) (Mesman et  al. 
2013). Thyroid parameters assessments have been part 
of all four measurements, and (Hillegers et al. 2007) have 
described the results of 5-year follow-up in detail. At 
12-year follow-up, at least one blood sample was avail-
able of 103 offspring subjects and 121 parents (bipo-
lar index parent N  =  63 and co-parent N  =  58) from 
69 bipolar family trios. The control group consisted of 
50 age- and gender-matched subjects and was enrolled 
through medical staff via our departments.
Bipolar twins
Thyroid parameters have been measured at baseline and 
6-year follow-up in BD and control twins. Vonk et  al. 
(2007) have described the results at baseline. At 6-year 
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follow-up, 53.2% of the BD twins, respectively, 45.7% of 
the control twins dropped out from the study. 25 twin 
pairs affected with BD (10 MZ discordant, 2 DZ concord-
ant, and 13 DZ discordant) and four twins from incom-
plete twin pairs (two DZ co-twins from discordant pairs, 
two MZ bipolar index twins from discordant pairs), and 
18 control twin pairs (10 MZ and 8 DZ) plus two MZ 
control twin from incomplete pairs were followed over 
time. In addition, we included 4 new enrolled twin pairs 
with BD (2 MZ concordant, 2 DZ discordant) and 1 twin 
from an incomplete pair (one MZ co-twin from concord-
ant pair), and 9 new enrolled control twin pairs (5 MZ, 4 
DZ) plus one MZ and one DZ control twin from incom-
plete pairs. Control twins were matched for age, gender, 
and zygosity.
Psychopathology
Psychiatric status of offspring and twins at the last meas-
urement was determined based on the SCID-I (Struc-
tured Clinical Interview for DSM-IV) (First et al. 1997). 
Psychiatric diagnosis of the parents was based on the 
International Diagnostic Checklist (Hiller et  al. 1993), 
Family History Research Diagnostic Criteria (FH-RDC) 
(Andreasen et al. 1977) method, and confirmative infor-
mation from the treating psychiatrist. See Table 1 for an 
overview of the psychopathology.
Autoantibody- and thyroid hormone-related assessments
We refer to our previous papers for a detailed description 
and methodology of the thyroid parameter assessments 
(Vonk et al. 2007; Hillegers et al. 2007).
Statistical analysis
Statistical analyses were performed using SPSS Statistics 
22.0. The seroprevalence of TPO-abs (>25 U/ml) between 
various groups was analyzed as dichotomized variable 
(positive/negative) with a Chi-square test. Correlations 
were determined using Spearman’s rank correlation 
coefficient (rs). The absolute TPO-Abs values were non-
normally distributed; a log transformation was applied. 
The log TPO-Abs values and covariates (age and gender) 
were pairwise analyzed using repeated measures analy-
sis of covariance (ANCOVA). A detailed explanation of 
this analysis can be found in Vonk et  al. (2007). Results 
were adjusted for multiple tests with the Bonferroni cor-
rection (i.e., by dividing the probability level of p < .05 by 
the number of performed tests, which resulted in a sig-
nificance threshold of p = .002).
Results
Stability of TPO-Abs over time
5 DBO subjects and 5 twins (4 healthy controls and 1 BD 
index) developed TPO-Ab positivity in the time frames 
of the study (6 resp. 12  years). Switching from TPO-ab 
negativity to TPO-Ab positivity was not related to the 
presence of a BD diagnosis or other psychopathology 
(data not shown). Only one twin (non-bipolar co-twin) 
switched from positivity (239  IU/ml) during the first 
measurement toward negativity this time (6.66  IU/ml). 
An exploratory analysis using a Spearman’s rank correla-
tion showed a positive correlation of TPO-Ab positivity 
over time in offspring and twins (rs =  .82 p < .001, resp. 
rs = .72, p < .001). Due to the in general TPO-Ab stabil-
ity over time, we investigated the relationship between 
TPO-Ab and psychopathology in twins and offspring at 
endpoint of follow-up (6 resp. 12 years).
TPO-Abs association with lithium-exposure
Lithium-exposed subjects did not differ significantly 
from lithium non-exposed subjects with respect to prev-
alence or positive TPO-Ab titers in all samples (data not 
shown).
TPO-Abs in familial and twin studies, also in relation to the 
diagnosis of BD
Bipolar family trios
Similar to our previous reports, the prevalence of TPO-
ab positivity in DBO was higher (10, 4% versus 4%), 
yet this difference lost significance compared to previ-
ous findings at baseline (p  =  .22). However, it must be 
noted that 5 of the 11 TPO-Abs positive DBO cases of 
2004 were lost to follow-up (Table 1). In the DBO cohort, 
TPO-Abs positivity was independent from the vulner-
ability to develop a mood disorder; of the 11 TPO-Abs 
positive subjects, 9.1% were bipolar, 54.5% unipolar, 
and 36.3% had no disorder, whereas of the 92 TPO-Abs 
negative subjects, 14.1% were bipolar, 39.1% unipolar, 
and 26,1% had no disorder and 20.7% other disorders 
(p =  .33). With regard to the parents, TPO-Abs positiv-
ity was not related to BD; 12.7% of the bipolar parents 
(n =  63) compared to 12.1% of the co-parents (n =  58) 
were TPO-Abs positive (p = .56) (Table 1).
Twin cases
Bipolar subjects (n = 36) and their non-bipolar co-twins 
(n = 27) showed an increased prevalence compared with 
controls (n  =  58) (27.7 resp. 25.9 resp. 13.8%), but dif-
ferences did not reach statistical significance (p  =  .20) 
(Table  1). Using an ANCOVA (adjusted for age and 
gender) on log-transformed absolute TPO-abs values, 
borderline significant higher TPO-abs levels in bipolar 
patients (n = 36) as compared to controls (n = 58) were 
found (mean 1.09  IU/ml (SD .77) resp. mean .82  IU/ml 
(SD .67), p  =  .076), the log-transformed TPO-abs val-
ues of the non-bipolar co-twins (n =  27) were between 
those of the bipolar patients and control twins (mean 
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1.06 IU/ml (SD .82, p =  .83 resp. p =  .23). In the previ-
ous study of Vonk et al. (2007), differences in mean levels 
of absolute TPO-Abs values (using a logarithmic trans-
formation) reached significance, i.e., bipolar patients had 
higher mean TPO-Abs levels compared to control twin 
pairs (p = .02). A pairwise repeated measures ANCOVA 
on the log-transformed absolute TPO-Abs values showed 
higher levels in the discordant BD twin pairs compared 
to control pairs (mean 1.11 IU/ml (SE .11) mean .84 IU/
ml (SE .12), p = .12), particularly in MZ discordant twin 
pairs. Differences were not found in mean log-trans-
formed TPO-Abs levels between BD index and non-
bipolar co-twins. All these findings are consistent with 
previous results (Vonk et al. 2007), yet were now not sig-
nificant (probably due to the smaller sample size).
Discussion
We here show that the prevalence and titer of TPO-Abs 
is bye-and-large stable over a time span of 6–12 years in 
two cohorts. This is in accord with the view that there is 
a bye-and-large stability in the prevalence of TPO-Abs in 
age groups of 20–60 years of age (females 10–20%, males 
2–8%) with a sharp increase in prevalence of TPO-Abs 
positivity during aging in men over 60 years of age (Bjoro 
et al. 2000; Rosmalen et al. 2001). These findings indicate 
that TPO-abs positivity should be considered as a ‘trait’ 
marker, rather than being related to mood state.
Similar to previous reports, increased rates of sero-
positivity and levels of TPO-abs in relatives (offspring or 
co-twin) of bipolar index cases as compared to controls 
were observed, irrespective of the presence of a mood 
disorder. However, in contrast to earlier studies, the 
results were not significant; while in the previous series 
of 2004, just significant values of p = .05 and p < .05 were 
found in DBO and BD twins respectively and in the sec-
ond series of 2010, these significant values were absent 
(p =  .22. and p =  .12). We assume that the significance 
discrepancy between the initial and follow-up studies 
can be explained by the power limitations of the studies 
and the fact that 5 of the 11 TPO-abs-positive DBO cases 
of 2004 were lost at follow-up. Assuming that TPO-Abs 
positivity is stable during the follow-up (see results), the 
prevalence of TPO-Abs positivity remains significantly 
increased compared to controls (p  =  .04), when taking 
into account earlier data of the 5 drop-outs at follow-up.
For the twins,  >45% were lost at follow-up compared 
to the previous measurement, even though a few new 
pairs were enrolled and included in the analysis, the sam-
ple size was still small (N =  121). Our findings of bor-
derline (non-) significant differences in the follow-up of 
both cohorts are congruent with the mixture of positive 
and negative reports (Bartalena et al. 1990; Kupka et al. 
2002; Radhakrishnan et  al. 2013; Haggerty et  al. 1997; 
Cobo et al. 2015; Vonk et al. 2007; Oomen et al. 1996) on 
a genetic association of BD and thyroid autoimmunity 
and our inability to detect a higher prevalence of TPO-
Abs in the bipolar parent of the DBO study. The major 
drawback of these conflicting studies on the familial 
relationship between major mood disorders and thy-
roid autoimmunity is often the sample size. Large num-
bers have been obtained in nationwide epidemiological 
studies which have—with the insight of today—a more 
advanced and sensible set-up given the limitations of the 
small-scale cohort studies. A recent Danish nationwide 
study reported that autoimmune diseases are risk fac-
tors for subsequent mood disorders; the incidence rate 
ratio (IRR) for autoimmune thyroiditis was 1.05 (.72–
1.52 95% CI) in mood disorder patients without chronic 
infections and 1.63 (1.09–2.23 95% CI) for mood disor-
der patient with chronic infections (Benros et  al. 2013). 
The IRR was even higher for Graves’ disease, namely 1.28 
(1.12–1.45 CI) in mood disorder patients without infec-
tions and 1.90 (1.63–2.21 CI) for mood disorder patients 
with infections. In general, a prior hospital contact 
because of autoimmune disease or any history of hospi-
talization for infection increased the risk for later mood 
disorder diagnosis by 45% (IRR, 1.45; 95% CI 1.39–1.52) 
resp. 62% (IRR, 1.62; 95% CI 1.60–1.64) (Benros et  al. 
2013). GWAS studies in psychiatric and autoimmune 
patients support the view of shared genetically deter-
mined abnormal immune interactions (The Network and 
Pathway Analysis Subgroup of the Psychiatric Genom-
ics Consortium 2015). These associations are compat-
ible with the immune hypothesis for the development of 
mood disorders in at least a subgroup of mood disorder 
patients. However, we are not able to identify this sub-
group of mood disorder patients since our studies do not 
find a direct relationship between psychopathology and 
the presence of TPO-Abs. Hence, future research should 
be directed toward investigating TPO-Abs in larger BD 
samples, also in relation to clinical features. Based on our 
results, we do not recommend screening for TPO-Abs 
in BD patients and first-degree relatives, as a marker for 
mood disorder vulnerability. Although in the presence of 
thyroid-related symptoms or aberrant thyroid hormone 
levels, determination of TPO-abs might be important as 
part of the clinical diagnostic work-up.
Collectively, our previous and present and particularly 
data from epidemiological and GWAS studies support the 
view that there is an increased inherited risk of co-occur-
rence of severe mood disorders and chronic recurrent 
infections and autoimmunity, including thyroid autoim-
munity, the latter only with a limited OR of between 1 and 
2. This means that only large-scale studies will unveil the 
association mood disorder-thyroid autoimmune disease 
as measured by the prevalence of TPO-Abs.
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